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Abstract
Antibody-enhanced replication (AER) of dengue type-2 virus (DENV-2) strains and production of antibody-enhanced disease
(AED) was tested in out-bred mice. Polyclonal antibodies (PAbs) generated against the nonstructural-1 (NS1) glycoprotein
candidate vaccine of the New Guinea-C (NG-C) or NSx strains reacted strongly and weakly with these antigens, respectively.
These PAbs contained the IgG2a subclass, which cross-reacted with the virion-associated envelope (E) glycoprotein of the
DENV-2 NSx strain, suggesting that they could generate its AER via all mouse Fcc-receptor classes. Indeed, when these mice
were challenged with a low dose (,0.5 LD50) of the DENV-2 NSx strain, but not the NG-C strain, they all generated dramatic
and lethal DENV-2 AER/AED. These AER/AED mice developed life-threatening acute respiratory distress syndrome (ARDS),
displayed by diffuse alveolar damage (DAD) resulting from i) dramatic interstitial alveolar septa-thickening with
mononuclear cells, ii) some hyperplasia of alveolar type-II pneumocytes, iii) copious intra-alveolar protein secretion, iv) some
hyaline membrane-covered alveolar walls, and v) DENV-2 antigen-positive alveolar macrophages. These mice also
developed meningo-encephalitis, with greater than 90,000-fold DENV-2 AER titers in microglial cells located throughout
their brain parenchyma, some of which formed nodules around dead neurons. Their spleens contained infiltrated
megakaryocytes with DENV-2 antigen-positive red-pulp macrophages, while their livers displayed extensive necrosis,
apoptosis and macro- and micro-steatosis, with DENV-2 antigen-positive Kuppfer cells and hepatocytes. Their infections
were confirmed by DENV-2 isolations from their lungs, spleens and livers. These findings accord with those reported in fatal
human ‘‘severe dengue’’ cases. This DENV-2 AER/AED was blocked by high concentrations of only the NG-C NS1
glycoprotein. These results imply a potential hazard of DENV NS1 glycoprotein-based vaccines, particularly against DENV
strains that contain multiple mutations or genetic recombination within or between their DENV E and NS1 glycoprotein-
encoding genes. The model provides potential for assessing DENV strain pathogenicity and anti-DENV therapies in normal
mice.
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Introduction
Dengue viruses (DENVs), which occur as four discrete
serotypes, are the most important vector-borne human viruses
[1]. Dengue hemorrhagic fever and dengue shock syndrome
(DHF/DSS), which are the most severe forms of disease were
previous classified into four grades (DHF I to IV) [2], but have
now been re-classified through a TDR/WHO program [3], in
which human ‘severe dengue’ cases that require urgent emergency
treatment have been characterized by: i) severe plasma leakage
leading to dengue shock and/or fluid accumulation with
respiratory distress, ii) severe hemorrhages, or iii) severe organ
impairment (hepatic damage, renal impairment, cardiomyopathy,
encephalopathy or encephalitis) [3]. DHF/DSS cases result from
the over-activation of patients’ immune responses, usually during
secondary DENV infections with virulent heterologous DENV
serotypes [4]. The severity of clinically-graded DHF/DSS directly
correlated with the plasma levels of the complement anaphylotox-
ins (C3a and C5a), histamine, particular cytokines (e.g. IFN-c,
TNF-a, IL-1, IL-6 and IL-10), and chemokines (e.g. IL-8 and
MIP-1), with increased clearance of the C1q (complement)
glycoprotein [5,6]. Numerous studies have shown that IgG
antibodies generated against the DENV virion-associated envelope
(E) and pre-membrane (prM) glycoproteins can increase DENV
replication in Fcc receptor (FccR)-bearing cells in vitro when they
are diluted beyond their effective neutralizing titers [4]. Some
monoclonal antibodies (MAbs), however, generated enhanced
disease in mice when they were administered before challenge with
other flaviviruses, but without increased viral replication [7,8].
The terms antibody-enhanced replication (AER) and antibody-
enhanced disease (AED) were, therefore, proposed to clarify these
different in vivo findings [9], both of which were previously
described as antibody-dependent enhancement (ADE) [7,8]. The
greatest DENV AER was, however, obtained in vitro using
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during the acute-phase of DENV infections that subsequently
developed DHF/DSS [10], or at the age when most DHF/DSS
cases occurred [11]. Despite these findings and their importance
for understanding of DENV pathogenesis, the ability of undiluted
PAbs raised against DENV to subsequently generate AER of a
heterologous DENV serotype in vivo was assessed in only one study
[12]. In this study, approximately 50-fold increased DENV-2
titers, and longer durations of viremia were observed in monkeys,
but they did not develop disease symptoms [12]. DHF/DSS
patients generated much higher titers of DENV-specific antibodies
of the IgG1, than IgG2, subclasses during the acute-phase of
disease compared to those from DF patients [13], and which could
generate DENV AER in both FccRI- and FccRII-bearing cells
[14,15]. Antibodies of the human IgG1 and mouse IgG2a
subclasses are similar since they are stimulated by IFN-c, fix
complement and recruit ADCCs, and are uniquely bound by all
four FcR types, while those of the human IgG2 and mouse IgG1
subclasses are not stimulated by IFN-c, do not fix complement or
recruit antibody-dependent cytotoxic cells (ADCCs), and are only
bound by low affinity FcRs [16–18]. As such, the ability of DENV
E glycoprotein-specific antibodies to either neutralize or generate
AER was dependent on their ability to fix complement and,
therefore, their IgG subclasses [19].
The dengue virus nonstructural-1 (NS1) glycoprotein, which
provided Fc-dependent non-neutralizing antibody-mediated pro-
tection in animals [20,21], is a candidate vaccine proposed to
avoid the risk of DENV AER posed by generating unsustainable
neutralizing IgG titers against the virion-associated E/prM
glycoproteins [22]. We however previously showed that some
purified MAbs (e.g. MAb 1G5.3) generated against the DENV-2
NS1 glycoprotein, also cross-reacted with common epitopes on the
DENV envelope (E) glycoproteins, weakly neutralised them [23],
and also generated a dramatic DENV-2 antibody-enhanced
replication (AER) resulting in lethal antibody-enhanced disease
(AED) in mice [9]. In addition, MAb, 1G5.4-A1-C3 and mouse
PAbs generated against the DENV-2 NS1 glycoprotein in out-
bred (TO strain) or congeneic (H2 class II: B10 strain) mice, all
cross-reacted with human fibrinogen, platelets and endothelial
cells [24,25]. These PAbs generated by the low-responding (H2
d:
B10.D2N and BALB/c strains) mouse haplotype or the low-avidity
MAb 1G5.4-A1-H6 subclone, and the high-responding (H2
s:
B10.S strain) mouse haplotype or the high avidity MAb 1G5.4-A1-
C3 subclone, showed similar reaction patterns against the
immuno-dominant ELK/KLE-type epitopes as those generated
by DF and DSS patients, respectively [24,25]. In addition, MAb
1G5.4-A1-C3 more strongly reacted with the ELK/KLE-type
epitopes on the E glycoproteins of virulent (DHF/DSS-associated)
DENV-2 and DENV-3 strains [23]. Such PAbs were, therefore,
thought to play important roles in DENV AED, but which would
be dependent upon: a) the concentrations of their IgG subclasses
which could fix complement and recruit ADCCs, b) their relative
avidities for these epitopes on their DENV NS1 and E
glycoproteins, c) the relative concentrations of their DENV NS1
and E glycoproteins, d) the relative concentrations of fibrinogen,
platelets, endothelial cells or other auto-antigens against which
they cross-react, and d) the presence of complement, IFN-c and
ADCCs. Thus, we consider it to be absolutely essential to perform
these studies in vivo using undiluted PAbs.
The DENV titers present in different organs from DHF/DSS
patients have not yet been determined. Comparative studies have,
however, been performed on different organs from fatal DSS cases
using histo-pathology [5,26], DENV-isolation efficiencies [5,26], in
situ hybridization [27], and DENV-specific MAbs [27–30]. In
these studies, macrophages in their spleens, lungs and livers
contained DENVs or their antigens [5,24–28], as well as their
brain phagocytic microglia and astrocytes [28,29,31]. The spleen
and liver were major sites of DENV replication [27], and dramatic
DENV AER was generated in primary splenic macrophages (red
pulp), but not T or B cells (white pulp), using DHF/DSS patients’
PAbs in vitro [32]. DENV has frequently been isolated from DHF/
DSS patients’ livers [5,26], and histological analyses demonstrated
severe liver damage characterized by steatosis, necrosis and
apoptosis (pyknosis), with DENV antigen-positive Kuppfer cells
and hepatocytes [33,34], similar to, but less severe than, that
caused by yellow fever virus [35].
The great majority of these fatal DHF/DSS cases demonstrated
sufficiently severe lung histo-pathology to hinder gaseous exchange
which, therefore, contributed to hypoxia and metabolic acidosis
[26]. In a very large study of DHF/DSS autopsies, 85/100 (85%)
of them displayed dramatically increased infiltrations of mononu-
clear cells and megakaryocytes, with edematous septa containing
eosinophic precipitates [26]. These results, therefore, demonstrat-
ed that these lung pathologies observed in the majority (85%) of
these patients [26] were not due to therapeutic fluid overload,
which may also lead to respiratory distress [3]. Acute respiratory
failure was also reported to be the leading cause of death in DSS
patients who succumbed after plasma leakage was resolved [26].
Importantly, acute respiratory distress syndrome (ARDS) has
subsequently been reported to occur in patients with the most
severe DENV disease grades (DSS: DHF grades III and IV), was a
major cause child and adult deaths in some studies, and occurred
even when appropriate early hospital-based supportive therapy
was provided [36–39]. DENVs have increasingly been implicated
in causing ARDS [37], DSS was identified as the third most
common cause of ARDS in one study [36], and symptoms of ‘fluid
accumulation with respiratory distress’, have now been added as
symptoms of ‘severe dengue’ by the TDR/WHO steering
committee [3]. DSS-associated ARDS, as with other acute viral
diseases, occurs through the dramatic and diffuse alveolar damage
(DAD) due to edema and the infiltration of mononuclear cells,
which result from the excessive release of IFN-c and other
inflammatory mediators [26]. DSS-associated ARDS may also
cause multi-organ dysfunction syndrome (MODS) and dissemi-
nated intravascular coagulation (DIC), due to resultant metabolic
acidosis, which were also causes of DSS-associated mortalities [36–
39], as well as neurological disease [38]. Although rarer, DHF/
DSS-associated encephalopathy, myelitis, meningitis and enceph-
alitis, have been increasingly reported throughout the world, and
in some reports encephalopathy [40], myelitis or encephalitis [41]
were associated with poor prognoses. DENVs were the leading
cause of encephalitis (47%) in one DENV-endemic country (Brazil)
[42], caused 7% (28/401) of the encephalitis cases amongst those
with suspected viral CNS infections in a study conducted in
Jamaica [43], 7% in Indonesia [44], and the third highest cause of
viral encephalitis (4.6%) in a study conducted in Viet Nam, where
Japanese encephalitis virus was prevalent [45]. As a result, both
DENV encephalopathy and encephalitis are now classified as
criteria of ‘severe dengue’ in humans by the TDR/WHO steering
committee [3].
Traditionally, the normal route of assessing both active and
passive protection against DENV infections in animals has been by
the intra-cerebral challenge of mice [46], but this challenge route
is still extensively used for these purposes, and also to confirm the
attenuation of candidate DENV vaccines. This model has,
therefore, also been used to test the protective roles of non-
neutralizing antibodies generated against DENV NS1 glycopro-
teins [47–50], and capsid (C) proteins [51,52]. Despite using this
Dengue Virus AER/AED
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subsequently observed in the brains and livers of these mice were
similar [53], with both DENV structural (C and E) and non-
structural (NS1) proteins detected in them [54]. These results,
therefore, indicated that the DENV spread to their peripheral
organs when their blood-brain barrier was breached.
In this study, we tested whether PAbs raised against the DENV-2
NS1 glycoprotein could generate AER of two DENV-2 strains, one
ofwhich possesseda lessantigenicNS1glycoprotein,andresulted in
AED in out-bred mice under normal physiological conditions. The
virological findings were then supported by comparative histo-
pathological and immuno-histological studies on their lungs, brains,
spleens and livers, and also with those reported in DSS patients. In
addition we: 1) assessed whether detectable IgG2a antibodies were
generated in these mice, 2) attempted to block the AED with high
concentrations of the NS1 glycoprotein, and 3) attempted to isolate
the DENV-2 from samples of lung, spleen and liver of these mice.
Materials and Methods
Ethics statement
All animal experiments adhered to UK Home Office regulations,
in accordance with the UK Animals (Scientific Procedures) Act
1986, were performed in approved animal facilities under relevant
project and personal animal procedure licenses (PIL 70/6903), and
were approved by the London School of Hygiene and Tropical
Medicine (LSHTM) ethics committee. These animal experiments
also conformed to European guidelines (European Convention for
the Protection of Vertebrate Animals used for Experimental and
other Scientific Purposes: Council Directive 86/609/EEC).
Dengue virus growth in vitro
Low passage DENV-2 of the New Guinea-C (NG-C) prototype
strain and the NSx (NSx) strain, which was a putative American/
Asian genotype strain that possessed a less antigenic NS1
glycoprotein due to either amino acid substitutions or genetic
recombination, were obtained from John Aaskov (Queensland
Institute of Technology, Brisbane, Australia) and Colin Leake
(LSHTM, London, UK), respectively. Both of these DENV-2
strains were isolated from DF patients, they were specifically
identified by the DENV-2- E glycoprotein-specific MAb 3H5, and
limited cDNA sequence determination confirmed that they both
encoded the non-American DENV-2 genotype 390-asparagine (N)
residue in their E glycoproteins [55]. The growth of dengue viruses
in mammalian (Vero) cells, insect (C6/36) cells and in suckling
mouse brains were performed as described previously [23,25,56].
Viruses were cultured in Vero cells maintained in complete
medium 199 (MCGM: mammalian cell growth medium) and C6/
36 cells maintained in complete Leibovitz L-15 medium (ICGM:
insect cell growth medium). Cell-culture supernatants were
collected on day 4 and 8 after infection.
Purification of the DENV-2 virions and NS1 glycoproteins
The purification of DENV-2 virions from infected mammalian
(Vero) and insect (C6/36) cell-culture supernatants and the
immuno-affinity purification of the native multimeric form of the
DENV-2 extracellular/secreted (e/sNS1) glycoprotein from the
supernatants of infected mammalian cells were performed as
described previously [23–25]. For this study, polyethylene glycol
(PEG) precipitated DENV-2 virions from infected insect cell-
culture supernatants were purified by ultra-centrifugation on
sequential 20/50% (wt/wt) discontinuous and 20–50% (wt/wt)
continuous sucrose gradients. Fractions containing the purified
DENV-2 virions were then diluted and the DENV-2 virions
re-precipitated using PEG and, after centrifugation, they were re-
suspended in the minimal volume of buffer and stored at 280uC.
The native extracellular/secreted forms of DENV-2 NS1
(e/sNS1) glycoproteins were obtained from mammalian (Vero)
cell cultures infected with the DENV-2 (NG-C and NSx strains)
and maintained in medium 199 containing 3.5% foetal bovine
serum and antibiotics as described previously [24,25]. The
supernatants were then collected 4 and 8 days after infection, a
cocktail of protease inhibitors was added, they were made to
30 mM Tris/HCl (pH 7.4), 0.02% (wt/vol) NaN3 containing 7%
(wt/vol) PEG 8,000 (P2139, Sigma) with 0.4 M NaCl, and the
DENV was allowed to aggregate overnight at 4uC. Mammalian
(BHK) cells, which stably expressed the DENV-2 (16681 strain)
NS1 glycoprotein [57], was kindly provided by Michael Diamond
(Washington University School of Medicine, St. Louis, USA), and
maintained in RPMI medium containing 10% FBS and 3 mg/ml
puromycin (P8833, Sigma), and the supernatants were harvested
when the cells reached 90% confluent. Protease inhibitors were
then added, and they were made to 30 mM Tris/HCl (pH 7.4)
with 0.02% (wt/vol) NaN3. These supernatants were then clarified
by centrifugation at 8,000 xg, and slowly (1 ml/min) passed
through an immuno-affinity column containing 12 mg of MAb
2A5.1. After washing, the bound DENV-2 NS1 glycoproteins were
eluted in their native hexameric forms using 20 mM diethyl-
amine/PPB (pH 11.2), and fractions were immediately neutralized
as described previously [57,58]. Protein concentrations were
determined against standard concentrations of bovine serum
albumin (BSA) by the microtiter plate-adapted bicinchoninic acid
(BCA) protein assay (Pierce, USA).
Dengue virus growth in mice
Pathogen-free out-bred Tyler’s original (TO) mice, which were
previously used for active and passive protection experiments
against DENVs [9,56], were employed to test whether polyclonal
antibodies (PAbs), generated against immuno-dominant epitopes
on the DENV-2 NS1 glycoprotein [23–25] which cross-reacted
with these determinants on the DENV E glycoproteins [23], could
all generate DENV-2 AER/AED in vivo, as was initially reported
[9]. For this study, the DENV-2 strains were grown once in 1–2
day old pathogen-free out-bred suckling TO mice (Harlan-OLAC,
UK) as described [56] by injecting 10 ml of DENV-2-infected
supernatant by the intra-cerebral (i–c.) route under anaesthesia
using 3% (vol/vol) halothane (Rhone Merieux, Ireland) in oxygen
at 1 dm
3/min. When mice showed severe neuro-pathological
symptoms, they were killed by CO2 asphyxiation, frozen to –80uC,
thawed, and their brains were aseptically harvested. Foetal bovine
serum (50% vol/vol) in MCGM was added and brain homoge-
nates were prepared, clarified by centrifugation, the clarified 10%
(wt/vol) DENV-2-infected mouse brain extracts were collected,
and aliquots were stored at –80uC.
To determine the DENV-2 NG-C and NSx strain challenge
doses used in the subsequent DENV-2 AER/AED experiments,
four groups of 10 six week-old pathogen-free out-bred TO mice
(Harlan-OLAC, UK) were anaesthetised and challenged by the
intra-cerebral (i–c.) route with 40 ml of serial 10-fold dilutions of
the 10% (wt/vol) DENV-2-infected mouse brain homogenates
prepared in sterile RPMI-1640 medium. Severe morbidity in
which the mice showed severe respiratory distress and hind-leg
paralysis, which were classified as mortalities, were recorded daily
and when these mice were humanely killed. The dilution of
DENV-2 NG-C or NSx strains that caused 25% mortality
(0.5 LD50) was then determined.
For the DENV-2 AER/AED experiments, groups of 14-16
three-week old pathogen-free out-bred TO mice (Harlan-OLAC,
Dengue Virus AER/AED
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multimeric e/sNS1 glycoproteins of the DENV-2 NSx (group A),
NG-C (groups B and C), or ovalbumin (control protein) (group D)
emulsified in Freund’s complete adjuvant (FCA) by combined
intra-peritoneal (i-p.)/sub-cutaneous (s-c.) routes. Two weeks later,
each mouse was boosted with the same antigen dose contained in
PBS by the i-p. route. One week later (i.e. at six-weeks old), each
mouse was anaesthetised, a blood sample was obtained from their
retro-orbital sinus for the ELISA and PRNT assays, and they were
challenged by the i-c. route with 40 ml containing less than 0.5
LD50 (approximately 0.5 to 1.0610
3 pfu) of either the DENV-2
NSx (groups A, B and D) or NGC (group C) strains. Severe
morbidity, displayed as severe respiratory distress and hind-leg
paralysis, was classified as mortality, and was recorded over a 14
day period after which time no further ‘mortalities’ occurred;
when observed such mice were humanely killed using CO2. For
the DENV-2 AER/AED blocking experiments, three groups (A, B
and C) of 14–16 three-week old pathogen-free out-bred TO mice
(Harlan-OLAC, UK) were immunized with 10 mg of immuno-
affinity purified multi-meric e/sNS1 glycoprotein of the DENV-2
NG-C strain emulsified in FCA by combined i-p./s-c. routes. Two
weeks later, each mouse was boosted with the same antigen dose
contained in PBS by the i-p. route. One week later (i.e. at six-
weeks old), 250 ml of sterile protein-free RPMI medium (negative
control) was administered intra-cerebrally to each mouse in group
A immediately prior to, and at the same site as, the challenge with
40 ml containing ,0.5 LD50 (approximately 0.5 to 1.0610
3 pfu) of
the DENV-2 NSx strain. At the same time, each mouse in the
other groups received 500 mg of the purified native multi-meric
forms of the DENV-2 e/sNS1 glycoprotein of either the NSx
(group B) or NGC (group C) strains contained in 250 ml of protein-
free RPMI-1640 0.2 mm filter-sterilized medium, by the i-c. route
immediately prior to, and at the same site as, the challenge with
40 ml containing ,0.5 LD50 of the DENV-2 NSx strain. Severe
morbidity, displayed as severe respiratory distress and hind-leg
paralysis, was classified as mortality, and was recorded over a 14
day period after which time no further ‘mortalities’ occurred;
when observed such mice were humanely killed using CO2.
Kaplan-Meier survival curves were used for statistical comparisons
between these different mouse groups using MedCalc statistical
software version 11.3 ( http://www.medcalc.be/ ).
A group of 5 three-week old out-bred TO mice were also
immunized using the same dose, adjuvant and routes with the
immuno-affinity purified DENV-2 (16681 strain) NS1 glycopro-
tein from the BHK replicon.
Positive control mouse PAbs for the immunoblot assays were
prepared in a group of three-week old out-bred TO mice
immunized every three weeks with approximately 2610
5 pfu of
live DENV-2 (NG-C strain) by the i-p. route before blood was
collected and the sera stored at 280uC.
Mouse tissue samples
Brains were aseptically collected from some of the mice 14 days
after challenge with the DENV-2 NSx strain, weighed and 10%
(wt/vol) DENV-2-infected mouse brain homogenates were
prepared as described above. The DENV-2 titres were determined
by plaque assays in 48-well cell-culture plates (Costar, USA). For
these assays, serial 10-fold dilutions from 1/10 were prepared in
250 ml of MCGM and 250 ml of MCGM containing 2610
5 Vero
cells/well were added. Each well was subsequently overlaid with
500 ml of 1.5% (wt/vol) carboxy-methylcellulose (C5678, Sigma)
prepared in MCGM. The wells were incubated for 7 days, fixed
with 8% (wt/vol) formaldehyde, washed, stained with 0.01%
(wt/vol) crystal violet in PBS, washed again with H2O, and
air-dried. The average DENV-2 titers (plaque forming units/gram
of mouse brain material) were determined by multiplying the
average numbers of plaques/well x 4 (= plaques/ml) x the log10
dilution x 10. In addition, lungs, spleens and livers from the
DENV-2 AER/AED mouse group (n=4) which died 8–9 days
after DENV-2 NSx strain challenge were collected after storage of
these mice at 280uC. These tissues were aseptically teased and
homogenised in ICGM using 3 ml mini-glass tissue homogenizers
(GP/20402, Camlab, UK), clarified by centrifugation and the
supernatants were used to infect 25 cm
2 C6/36 insect cell
monolayers. After incubation at 28uC for 7 days, the supernatants
were collected and clarified by centrifugation. After discarding the
supernatants, the cells were re-suspended in a minimum volume of
PBS added to 12-well polytetrafluoroethylene- (PTFE-) coated
immuno-fluorescent slides (Hendley, UK), air-dried, fixed with
cold (-20uC) acetone, again air-dried and stored at 220uC (see
immunoassays).
Histological studies
Mouse brains, lungs, spleens and livers were aseptically collected
on day 14 after virus challenge, placed on 2 cm diameter cork discs
and covered with Tissue Tek OCT compound (PELCO Interna-
tional, USA), slowly frozen and stored at 280uC. Six mm tissue
sections were cut using a cryotome and placed on slides which were
fixed with cold (220uC) acetone, ethanol and again with acetone,
air-dried and stored at –80uC. Some of these slides were stained
usingstandard ironhematoxylinandeosin(H&E).Alternatively,the
sections were wetted with PBS, before a 1/1000 diluted pool of DF
patients sera that had a high ELISA titer (mean ELISA reciprocal
log10t50 5.83) against the E glycoproteins on purified DENV-2
(NSx strain) virions, but reacted very weakly with its NS1
glycoprotein (mean ELISA reciprocal log10t50 2.25), were reacted
withthe sectionsfor 1 hrat25uC. Afterwashing with PBS, A FITC-
labelled goat anti-human IgG (H and L) (109-095-088: Jackson
ImmunoResearch, USA), diluted at 1/1000 containing 0.03%
(wt/vol) Evan’s blue, was then reacted with the sections for 1 hr at
25uC. After washing with PBS, and briefly (3 secs) in H2O, they
were mounted in 90% glycerol/PBS pH 8.0. Photomicrographs
were taken for 4–6 mins using the appropriate excitation and
barrier filters on Fujichrome Sensia 400 film (Fuji Inc. Japan) and
subsequently converted to digital format. For these studies,
megakaryocytes and the DENV-2 target tissue macrophages in
the liver (Kuppfer cells), lungs (alveolar macrophages), spleen
(red-pulp macrophages) and brain (microglia cells) were identified
by their characteristic morphologies according to i) mouse histolo-
gical atlases [ http://ctrgenpath.net/static/atlas/mousehistology/
Windows/introduction.html , http://www.deltagen.com/target/
histologyatlas/HistologyAtlas.html , http://tvmouse.compmed.ucdavis.
edu , http://www.mbl.org/atlas170/atlas170_frame.html ], ii) histo-
pathological descriptions and photo-micrographs from patients with
DENV acute respiratory distress syndrome (ARDS) [5,26,59], iii)
megakaryocyte infiltration of patients’ organs during DENV infections
[5,26] or in the spleens of genetically modified (knockout) mice [60],
and, iv) DHF/DSS patients’ liver samples [5,26,33,34] that showed
DENV- infected Kuppfer cells [61]. The histological findings in the
brains of the DENV AER/AED mice were also compared with
encephalitis in humans or mice caused by West Nile virus [62], Saint
Louis encephalitis virus (slide 109) [ http://www.urmc.rochester.edu/
neuroslides ] and Japanese encephalitis virus [63].
Immunoassays
The indirect ELISAs and immunoblot assays, using the
immuno-affinity purified native hexameric DENV-2 e/sNS1
glycoproteins and purified DENV-2 virions, were performed as
Dengue Virus AER/AED
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0.6 mg/ml (purified DENV-2 virions) or 1.5 mg/ml (purified
DENV-2 NS1 glycoproteins), they were blocked using 1%
(wt/vol) gelatin in PBS. After PBS washing, serial PAb or MAb
dilutions were reacted. After washing, the bound PAbs were
detected by sequential reaction steps using a peroxidase-labelled
goat anti-mouse IgG (H & L) (115-035-062, Jackson ImmunoR-
esearch diluted to 1/2000, washing, and addition of standard
o-phenylenediamine dihydrochloride substrate solution containing
H2O2. After stopping the reaction with 0.2M H2SO4, the
absorbance values were measured at a dual wavelength of 490
and 620 nm (MRX, Dynex) and the average reciprocal log10 50%
end-point ELISA titers (1/log10t50) were determined.
The plaque-reduction neutralisation tests (PRNTs) were per-
formed in 48-well plates using serial dilutions of both the DENV-2
NG-C and NSx strains from infected C6/36 supernatants subse-
quentlydilutedinMCGMagainstserialpre-challengeserafrommice
and 2610
5 Vero cells/well were performed as described previously
[23,56]. These wells were then overlaid with 1.5% (wt/vol) carboxy-
methylcellulose/MCGM and after incubation at 37uCf o r7d a y st h e
cell monolayers were fixed with 8% formaldehyde, washed and
stained with 1% (wt/vol) crystal violet/PBS before further being
washed and dried (see above). The PAb dilutions which reduced the
numbers of DENV-2 plaques by 50% were then calculated.
To investigate the possible contamination of the immuno-
affinity purified DENV-2 e/sNS1 glycoprotein samples with the
DENV E and prM glycoproteins, high (960 ng) concentrations of
the purified DENV-2 (NSx strain) virions also obtained from
DENV-infected mammalian cells and 200 ng concentrations of
the purified e/sNS1 glycoproteins of the DENV-2 16681, NG-C
and NSx strains were heated and subjected to 8% (wt/vol) non-
reducing SDS-PAGE. To identify the cross-reaction of PAbs
generated against the purified DENV-2 e/sNS1 glycoproteins of
the 16681, NG-C and NSx strains two (approximately 1000 ng
and 250 ng) concentrations of DENV-2 virions purified from
DENV-2 (NSx strain) infected C6/36 cell-culture supernatants
(see above) were heated at 100uC for 3 min before subjection to
9% (wt/vol) non-reducing SDS-PAGE. These gels were then
subjected to semi-dry electro-blotting onto 0.2 mm pore-sized
nitrocellulose membranes and air drying. After blocking with
PBS/M (see immuno-fluorescent assays), a 1/200 dilution of the
mouse or human PAbs, or 1 mg/ml of the IgG2a subclass MAb,
specific for the DENV-2 NS1 (MAb 2A5.1), E (MAb 2C5.1) or
prM (MAb 2A4.1) glycoproteins [23], were reacted with these
membranes. After washing, the bound PAbs were detected by
sequential reaction steps using a 1/2000 dilution of the
peroxidase-labelled anti-mouse IgG2a-specific second PAbs (115-
035-206, Jackson ImmunoResearch, USA), washing and standard
3,39 diaminobenzidine tetrahydrochloride/4-chloro-1-naphthol
(CND) substrate mixture containing H2O2.
Immuno-fluorescent antibody (IFA) assays to detect DENV-2
infected C6/36 cells were performed as described previously [64].
For these assays, MAb 3H5 specific for the envelope (E)
glycoprotein DENV-2 was diluted to 1/100 in PBS containing
2% milk powder (Marvel, Cadbury’s, UK) and reacted with the
fixed C6/36 cells on the IFA slides for 2 hr at 28uC. These slides
were then washed three times with PBS and gently blotted before
adding 10 ml of a 1/500 dilution of FITC-labeled goat anti-mouse
IgG (H&L) (115-095-062, Jackson ImmunoResearch, USA) and
incubated at 28uC for 1 hour. After washing again three times
with PBS, the slides were briefly dipped in distilled water, gently
blotted and mounted with 90% glycerol/PBS pH 8.3 and viewed
under immuno-fluorescent microscopy using the appropriate
FITC excitation and barrier filters.
Results
Affinity purified DENV NS1 glycoproteins did not contain
other DENV proteins
Since the NS1 glycoproteins were immuno-affinity purified from
DENV-2infected mammaliancells,we initiallytested whether these
preparations contained any contaminating DENV-2 E or prM
glycoproteins, which could affect the results. We also used a control
immuno-affinity purified NS1 glycoprotein recombinant expression
construct which expressed the NS1 glycoprotein of DENV-2 (16681
strain) in mammalian cells in the absence of genes encoding the
DENV-2 E and prM glycoproteins. In this study, no contaminating
E (gp60/55) or prM (gp20) glycoproteins were detected in
immunoblot assays using high (200 ng) concentrations of the
purified DENV-2 NS1 glycoproteins of the DENV-2 16681, NG-
C or NSx strains with MAbs specific for each of these DENV
glycoproteins (Figure S1).
Immunogenicity and antigenicity of NS1 glycoproteins of
different DENV-2 strains, and their ability to generate
DENV-2 E glycoprotein cross-reactive PAbs
The ability of normal out-bred mice to generate PAbs against
the native hexameric e/sNS1 glycoproteins of the DENV-2 16681,
NG-C or NSx strains, that cross-reacted with the virion-associated
E or prM glycoproteins was assessed. In this study, out-bred mice
repeatedly immunized with the NS1 glycoproteins of either the
DENV-2 16681, NG-C or NSx strains all generated high PAb
titres against the NS1 glycoprotein of the NG-C strain (mean
reciprocal log10t50 4.50, 4.33 and 4.13 respectively) (Table 1).
These PAbs, however, only weakly reacted with the NS1
glycoprotein of the DENV-2 NSx strain (mean reciprocal log10t50
2.82 (47.9-fold reduction), 2.68 (44.7-fold reduction) and 2.81
(20.9-fold reduction), respectively. The NS1 glycoproteins of the
DENV-2 16681, NG-C and NSx strains were, therefore, similarly
immunogenic, but that of the NSx strain was very weakly antigenic
in these ELISAs. The PAbs from each of the three mouse groups
showed similar cross-reactive titres against purified DENV-2
virions of the NSx strain (mean reciprocal log10t50 2.85, 2.78 and
2.65 respectively). Importantly, the PAbs generated against the
NS1 glycoproteins of the DENV-2 16681 and NG-C strains
showed higher mean ELISA titers against the virions, than the
NS1 glycoprotein, of the DENV-2 NSx strain strongly suggesting
that they were likely to generate AER of the DENV-2 NSx strain.
Whilst PAbs generated in mice to live DENV-2 infections showed
higher titers against the DENV-2 E glycoprotein, they also more
weakly reacted with the NS1 glycoprotein of the DENV-2 NSx
strain than the 16681 or NG-C strains.
The cross-reactions of the PAbs generated against the purified
NS1 glycoproteins of the DENV-2 16681, NG-C and NSx with
the virion-associated E or prM glycoproteins were further tested
using immunoblot assays. For this study, purified DENV-2 (NSx
strain) virions obtained from infected C6/36 mosquito cells were
used to more easily distinguish between the E (gp60 and gp55) and
NS1 (gp48) glycoprotein bands (Figure 1). In addition, the ability
to detect PAbs of the IgG2a subclass was assessed. In this study,
the PAbs generated against the purified e/sNS1 glycoproteins of
each DENV-2 strain all generated detectable PAbs of the IgG2a
subclass that reacted with the NS1 glycoprotein (gp48), and cross-
reacted with the E glycoprotein (gp60 and gp55) of the DENV-2
NSx strains, but not with its prM glycoprotein (gp20) (Figure 1).
All of these PAbs had a low plaque-reduction neutralisation titer
(PRNT) of 1/8 against both the DENV-2 NG-C and NSx strains,
suggesting that they may also generate DENV-2 AER. In contrast,
PAbs generated in mice against repeated live DENV-2 infections
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prM glycoprotein-specific MAbs, 2C5.1 and 2A4.1, strongly
reacted with the DENV-2 E and prM glycoproteins but less
strongly with the NS1 glycoprotein, while MAb 2A5.1 showed a
strong anti-DENV-2 NS1 glycoprotein-specific reaction. All of
their pre-immunisation PAb sera, as well as those generated
against ovalbumin (control glycoprotein), however, failed to cross-
react with any DENV-2 glycoproteins (Table 1, Figure 1).
Ability of PAbs raised against the NS1 glycoproteins of
DENV-2 strains to generate antibody-enhanced disease
(AED) in mice
Groups of out-bred mice immunized with either the NS1
glycoproteins of the DENV-2 NG-C or NSx strains and
challenged with a low dose (,0.5 LD50) of the live DENV-2
NSx strain all showed symptoms of severe respiratory distress and
hind-leg paralysis on, or before, day 14 after infection (Figures 2A
and 2B). Only 3/15 (20%) of the mice immunized with the NS1
glycoprotein of the DENV-2 NG-C strain and challenged with a
low dose (,1L D 50) of live DENV-2 NG-C strain, however,
showed symptoms of severe respiratory distress and hind-leg
paralysis on, or before, day 14 after challenge (Figure 2C), after
which no further cases of morbidity occurred. In contrast, only
1/14 (7.1%) of the mice immunized with the control protein,
ovalbumin (OA) and challenged with a low dose of the live
DENV-2 NSx strain displayed hind-leg paralysis on, or before, day
14 after challenge (Figure 2D), but this animal did not display
severe respiratory distress, and none of the other 13/14 animals
showed any signs of morbidity. These results using the control
mice therefore confirmed that the deaths that occurred in the
other mouse groups (2A, 2B or 2C) were not caused by another
Table 1. Mouse PAb and MAb reactions against DENV-2 virions and NS1 glycoproteins.
50% end-point (1/log10t50) ELISA titer (s.d.)
c
DENV-2 NS1 gp DENV-2 Virions
PAb/MAb
a Immunogen
b NG-C NSx NSx Ovalbumin
Mouse PAbs DENV-2 (16681) NS1 gp 4.50 (0.41) 2.82 (0.22) 2.85 (0.27) 1.76 (0.16)
Mouse PAbs DENV-2 (NGC) NS1 gp 4.33 (0.41) 2.68 (0.25) 2.78 (0.29) 1.84 (0.16)
Mouse PAbs DENV-2 (NSx) NS1 gp 4.13 (0.39) 2.81 (0.22) 2.65 (0.27) 1.71 (0.18)
Mouse PAbs Ovalbumin 0.87 (0.07) 0.80 (0.06) 1.11 (0.12) 4.66 (0.24)
Mouse PAbs DENV-2 (NGC) infections 3.38 (0.11) 2.15 (0.12) 5.25 (0.25) 1.21 (0.12)
MAb 2A5.1 DENV-2 (PR159) NS1 gp 5.86 (0.03) 5.81 (0.04) 0.60 (0.02) 0.41 (0.02)
MAb 2C5.1 DENV-2 (PR159) E gp 2.32 (0.02) 2.13 (0.02) 5.51 (0.03) 0.17 (0.01)
MAb 2A4.1 DENV-2 (PR159) prM gp 2.05 (0.02) 1.87 (0.01) 4.36 (0.04) 0.18 (0.01)
aMouse monoclonal antibodies (MAbs) specific for the NS1 (2A5.1), E (2C5.1) or prM (2A4.1) glycoproteins or polyclonal antibodies (PAbs) generated against DENV-2
infections or immuno-affinity purified DENV-2 NS1 glycoproteins, and which were collected immediately prior to challenge with either the DENV-2 NG-C or NSx strains.
bImmunogen as either the immuno-affinity purified NS1 glycoprotein (NS1 gp) of the DENV-2 16681, NG-C or NSx strains, ovalbumin (control protein) or repeated live
DENV-2 (NG-C strain) infections.
cThe mean reciprocal log10 50% end-point ELISA titer (1/log10t50) and standard deviation (s.d.) of pools of mouse PAbs or MAbs, against the immuno-affinity purified
NS1 glycoproteins of the DENV-2 NG-C or NSx strains, ovalbumin (control protein) or purified DENV-2 (NSx strain) virions, when detected using peroxidase-labelled goat
anti-mouse IgG (H&L) second antibodies. Mouse PAbs which had higher ELISA titers against the DENV-2 virions of the NSx strain than its NS1 glycoproteina r e
underlined.
doi:10.1371/journal.pone.0021024.t001
Figure 1. Immunoblot reactions of PAbs and MAbs against DENV-2 proteins. Approximately 1000 ng (odd numbered lanes) and 250 ng
(even numbered lanes) concentrations of purified DENV-2 (NSx strain) virions, obtained from infected C6/36 supernatants, were heated at 100uC for
3 min and subjected to 9% (wt/vol) non-reduced SDS-PAGE and immuno-blotting. These strips were then reacted with either 1/200 dilutions of
mouse PAbs generated against repeated infections with DENV-2 (NG-C strain) (lanes 1 and 2) or the pre-immunization (pre-i) and post-immunization
(post-i) sera pooled from mice that had been generated against the purified NS1 glycoproteins of the DENV-2 16681 (pre-i: lanes 3 and 4; post-i: lanes
5 and 6), NG-C (pre-i: lanes 7 and 8; post-i: lanes 9 and 10) or NSx (pre-i: lanes 11 and 12; post-i: lanes 13 and 14) strains or ovalbumin (pre-i: lanes 15
and 16; post-i: lanes 17 and 18) or 1 mg/ml of IgG2a subclass MAbs specific for the DENV-2 NS1 (MAb 2A5.1) (lanes 19 and 20) the DENV E and prM
glycoproteins (MAbs 2C5.1 and 2A4.1) (lanes 21 and 22) (Table 1). The bound MAbs were then detected using a peroxidase-labelled goat anti-mouse
IgG2a subclass-specific secondary PAbs and CND substrate. The locations of standard kilodalton (kD) molecular weight markers and the DENV-2 E
(gp60 and 55), NS1 (gp48) and prM (gp20) glycoproteins are shown.
doi:10.1371/journal.pone.0021024.g001
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were strongly supported by significant Kaplan-Meier survival
curve statistics (Figure 2: group A versus C: x2 20.91, p,0.0001;
group B versus C: x2 20.84, p,0.0001; group A versus D
(control): x2 30.04, p,0.0001; group B versus D (control): x2
29.87, p,0.0001). Thus, the immunization of out-bred mice with
the native NS1 glycoproteins of either the DENV-2 NG-C or NSx
strains generated PAbs that caused dramatic and statistically
significant, DENV-2 AED when they were challenged with the
DENV-2 NSx strain, but not the DENV-2 NG-C strain. These
results indicated that the DENV-2 AED was generated only when
the mice were immunized with DENV-2 NS1 glycoproteins and
challenged with the DENV-2 NSx strain, because of their
relatively stronger PAb reactions against its E glycoprotein, and
weaker (44.7-fold and 20.9-fold reduced) antigenicity of its NS1
glycoprotein (Table 1). To confirm this hypothesis, the ability of
the NS1 glycoproteins of the DENV-2 NG-C or NSx strains to
block the DENV-2 AED was tested. In this study, three groups
(A, B and C) of 14-16 three-week old out-bred mice were all
immunized with the immuno-affinity purified multi-meric e/sNS1
glycoprotein of the DENV-2 NG-C strain, and again boosted two
weeks later with the same antigen dose in PBS. One week later
(i.e. at six-weeks old), 250 ml of sterile protein-free RPMI medium
(group A: controls) was administered intra-cerebrally to each
mouse in group A immediately prior to, and at the same site as, the
challenge dose containing ,0.5 LD50 of the DENV-2 NSx strain.
Each mouse in the other groups received 500 mg of the purified
DENV-2 e/sNS1 glycoprotein of either the NSx (group B) or
NGC (group C) strains by the intra-cerebral route immediately
prior to, and at the same site as, challenge with ,0.5 LD50 of the
DENV-2 NSx strain. In this study, all of the mice immunized with
the DENV-2 NS1 glycoprotein, that received protein-free RPMI
medium prior to challenge with the DENV-2 NSx strain (group A:
controls) developed severe respiratory distress and hind-leg
paralysis on, or before, day 14 after infection (Figure 3A). The
immunized mice that were pre-injected with the NS1 glycoprotein
of the NSx strain immediately prior to challenge with the DENV-2
NSx strain (group B) showed a delayed onset of severe morbidity,
but they all subsequently succumbed to severe respiratory distress
and hind-leg paralysis on, or before, day 14 after infection
(Figure 3B). Despite these findings, a statistically significant
difference was obtained between these two groups (Figure 3: group
A versus B: x
2 7.10, p,0.008). In contrast, only 3/15 (20%) of the
immunized mice that were pre-injected with the NS1 glycoprotein
of the DENV-2 NG-C strain, immediately prior to challenge with
the DENV-2 NSx strain (group C), developed severe respiratory
distress and hind-leg paralysis on, or before, day 14 after infection.
The NS1 glycoprotein of the DENV-2 NGC strain therefore more
strongly blocked the DENV-2 AED, with 12/15 (80.0%) of these
mice surviving (i.e. showing no severe respiratory distress and/or
hind-leg paralysis) on day 14 after challenge (Figure 3C) (Figure 3:
group B versus C: x
2 23.84, p,0.0001). There was also no
significant difference between the blocking of AED by the NS1
glycoprotein of NG-C (Figure 3C) and the DENV-2 non-AED
mice immunised with ovalbumin (control glycoprotein) before
viral challenge (Figure 2D) (Figure 3 group C versus Figure 2
group D: x
2 1.07, p=0.302). Thus, the treatment of the mice with
the NS1 glycoprotein of the DENV-2 NG-C strain significantly
blocked all evidence of DENV-2 AER/AED, while the NS1
glycoprotein of the DENV-2 NSx strain failed to prevent AED,
probably due to its much weaker antigenicity (Table 1) (Figure 3:
group B versus Figure 2 group D: x
2 29.70, p,0.0001).
Figure 2. Ability of DENV-2 NS1 glycoproteins to generate DENV-2 AED. Groups of 14-16 out-bred mice were repeatedly immunized with
the DENV-2 NS1 glycoproteins of either the NSx (NSx-NS1) (Group A), NG-C (NGC-NS1) (Group B and C) strains, or ovalbumin (OA) (Group D)
(immunogens) by the combined i-p./s-c. route, and challenged by the intra-cerebral route with a low (,0.5 LD50) dose of either the DENV-2 NSx
(Group A, B and D) or NG-C strain (Group C). The survival (%) for each group is shown from day 7 to 14 after DENV-2 challenge by colored bars and
Kaplan-Meier survival curves were compared to obtain statistical values for groups A versus B (x2: 0.06; p=0.81), A versus C (x2=20.91; p,0.0001), A
versus D (x2=20.80; p,0.0001) and B versus C (x2=20.80; p,0.0001).
doi:10.1371/journal.pone.0021024.g002
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after challenge to confirm that the AED was caused by DENV-2
AER. Since the high lipid and protein concentrations in these
homogenates affected DENV-2 plaque-formation, initial dilutions
were started at 1/10 of the 10% (wt/vol) brain homogenates
(i.e. 1/100 dilution/gram of brain homogenate). In these assays,
the DENV-2 AED mice tested (n=6) showed consistent DENV-2
AER with an average DENV-2 NSx strain titer of 8.5610
7
(standard deviation 2.6610
6) plaque-forming units/gram of brain
homogenate, while no plaques could be detected in brain
homogenates of the non-AER/AED animals at the starting
dilution of 1/400. The average DENV-2 NSx strain AER was
therefore at least 90,000-fold, but was likely to be higher since
DENV-2 E glycoproteins could not detected in the brains of the
DENV-2 non-AER/AED mice by immuno-histology (see later). A
dramatic AER of the DENV-2 NSx strain which resulted in
DENV-2 AED was, therefore, confirmed in these animals.
DENV-2 was also isolated from lung, spleen and liver
homogenates from each of four DENV AER/AED mice that
died on day 8-9 after challenge using C6/36 cells. These results,
therefore, confirmed that the DENV-2 NSx strain had spread to
infect these peripheral organs.
Histological studies on organs from the DENV-2 AER/AED
mice and non-AER/AED mice
Normal histological and immuno-histological analyses on
various organs of the DENV-2 AED mice (groups A and B from
Figure 2A and 2B) and DENV-2 non-AER/AED mice (group D
from Figure 2D), collected on day 14 after infection, were
performed to i) contrast the pathologies observed in these organs,
ii) identify the DENV-2 antigen-positive cell-types in these organs,
and iii) compare these results with those reported in DHF/DSS
patients’ organs. In this study, the DENV-2 AED mice (groups A
and B) all showed severe meningitis and displayed dramatic
mononuclear cell infiltration, predominantly of lymphocytes and
plasma cells, over a background of fibrinoid material (Figure 4A).
The encephalitis was characterized by the presence of eosinophil-
ic-staining dead neurones and lymphocytic infiltration of the brain
parenchyma, with the formation of microglial cell nodules around
necrotic neurons (Figures 4A and 4B). Perivascular lymphocytic
cuffing, composed mainly of lymphocytes and plasma cells with a
thickness ranging from 2-5 cell layers, was evident in the brain
hemispheres (Figures 4A and 4B). Interestingly, DENV-2 E
glycoproteins were not identified in the mononuclear cells within
either the meninges or the perivascular infiltrate in the brain
parenchyma, but were identified in the phagocytic microglial cells,
including those that formed nodules throughout the brain
parenchyma (Figure 4C). These histopathological changes were
predominantly observed in the grey matter, consistent with its
higher density of neurons. The microglial nodule formation and
apoptotic neurones observed in the DENV-2 AER/AED mice also
accorded with histological studies on encephalitis in humans or
mice caused by neurotropic flaviviruses (e.g. West Nile [62] or
Japanese encephalitis [63] viruses). In contrast, the DENV-2 non-
AED mice (group D) showed normal meninges and brain
parenchyma (Figures 4D and 4E), consistent with the inability
Figure 3. Ability of DENV-2 NS1 glycoproteins to block the DENV-2 AED. Groups of 14-16 out-bred mice were repeated immunized with the
immuno-affinity DENV-2 NS1 glycoprotein of the NG-C strain (NGC-NS1glycoprotein immunogen) by the combined i-p./s-c. route, and either pre-
treated intra-cerebrally with protein-free RPMI medium (A), or pre-treated intra-cerebrally with 500 mg of the purified NS1 glycoproteins of either the
DENV-2 NSx strain (NSx-NS1) (B) or the NG-C strain (NGC-NS1) (C), immediately prior to and at the same intra-cerebral site as the subsequent
challenge with a low dose (,0.5 LD50) of the DENV-2 NSx strain. The survival (%) for each group is shown from day 7 to 14 after challenge by colored
bars and Kaplan-Meier survival curves were compared to obtain values for groups A versus B (x2=7.10; p ,0.008), A versus C (x2=27.46; p,0.0001)
and B versus C (x2=23.84; p,0.0001).
doi:10.1371/journal.pone.0021024.g003
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tissues (Figure 4F).
The lungs of the DENV-2 AER/AED mice showed dramatic
edema and a severe state of acute respiratory distress syndrome
(ARDS) displayed by diffuse alveolar damage (DAD), with the
extensive thickening of the alveolar walls by the infiltration of
macrophages and lymphocytes and occasional hyperplasia of
alveolar type II pneumocytes (Figure 5A). In addition, there was
copious intra-alveolar proteinaceous secretion with the occasional
formation of hyaline membrane-covered alveolar walls. DENV-2
E glycoproteins were present in their alveolar macrophages, which
had characteristic morphologies (data not shown). These findings
were therefore typical of life-threatening ARDS, thereby account-
ing for the severe symptoms of respiratory distress displayed by
these animals. In contrast, the DENV-2 non-AER/AED mice
showed a slight degree of edema in their lungs, but many alveolar
walls were still one cell thick, there was no hyaline membrane
formation (Figure 5B), and no DENV-2 E glycoproteins were
detected in their alveolar macrophages. These results therefore
accorded with the histo-pathological descriptions of lung pathol-
ogy observed in fatal DHF/DSS cases, in which oxygen-exchange
was severely inhibited [26], and as was observed in histological
photomicrographs obtained from a fatal DHF/DSS case [59]. The
livers of the DENV-2 AER/AED mice displayed extensive
necrosis and micro- and macro-steatosis, with many cells diplaying
pyknosis (apoptosis) (Figure 5C). DENV-2 E glycoproteins were
identified in many Kuppfer cells with their characteristic
morphologies [61], and hepatocytes using immuno-fluorescent
microscopy (data not shown). The DENV-2 AER/AED mice,
therefore, demonstrated severe liver disease, while the DENV-2
non-AER/AED control mice displayed normal liver histologies.
These results therefore accord with those described in fatal cases of
‘severe dengue’ disease in humans [5,26,33,34]. High numbers of
megakaryocyte (platelet precursor) cells, with their characteristic
multi-lobed nuclei, had infiltrated the spleens of the DENV-2
AER/AED mice, and DENV-2 E glycoproteins were identified in
many of the macrophages located throughout the red pulp, but in
only relatively low numbers of cells in the white pulp (Figures 5D,
5E and 5F). The DENV-2 non-AER/AED mice also showed
some infiltration of megakaryocytes in their spleens (data not
shown), but DENV-2 E glycoproteins were not detected in their
spleens. These results, together with the ability to isolate DENV-2
from lung, spleen and liver homogenates from the DENV AER/
AED mice on day 8–9 after challenge, therefore, confirmed that
the DENV-2 NSx strain had spread to infect the peripheral
organs, probably when the blood-brain barrier was breached
during DENV-2 challenge, and when bleeding was observed at
these injection sites.
Discussion
The main findings from this study were: 1) that PAbs generated
against the DENV-2 NS1 glycoprotein could cross-react with the
E glycoprotein and generate the highest DENV ($90,000-fold)
AER titers so far reported in vivo using undiluted PAbs with a wild-
type DENV-2 strain, 2) that this dramatic DENV-2 AER/AED
Figure 4. Comparative DENV-2 AER/AED and non-AER/AED mouse brain histologies. Representative DENV-2 AER/AED mouse brain
sections (A, B and C) from group A/B mice (Figure 2A/B) and DENV-2 non-AER/AED mouse brain sections (D, E and F) from group D mice (Figure 2D),
immunized with either the NS1 glycoprotein of the DENV-2 NSx strain or ovalbumin by the combined i-p./s-c. routes, respectively, prior to challenged
with the DENV-2 NSx strain by the i-c. route, collected on day 14 after challenge. Cryostat-cut sections were either stained with standard hematoxylin
and eosin (H&E) (A, B, D and E) or tested in immuno-fluorescence antibody (IFA) assays using human PAbs reactive against the DENV E glycoprotein
and FITC-labelled secondary PAbs. The DENV-2 AER/AED mouse meninges showed extensive mononuclear cell infiltration (arrowed) with microglial
nodule formation and many eosinophilic-staining dead neurones (asterixed) (100x: 100 mm bar) in their brain parenchyma (A). The DENV-2 AER/AED
mouse microglial nodules were located throughout their brain parenchyma (arrowed) and blood vessels showed perivascular cuffing with
mononuclear cells (asterixed) (200x: 50 mm bar) (B). DENV-2 E glycoproteins were present in the microglial cells, including those which formed
nodules (arrowed) throughout their brain parenchyma, but not in the mononuclear cells in the perivascular infiltrate (asterixed) (400x: 20 mm bar)
(C). In contrast, the DENV-2 non-AER/AED mice showed normal meninges (arrowed) (100x: 100 mm bar) (D) and no pathological changes in their brain
parenchyma (200x: 50 mm bar) (E) and no DENV-2 E glycoproteins were present in these cells (400x: 20 mm bar) (F).
doi:10.1371/journal.pone.0021024.g004
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another DENV-2 strain, 3) that DENV-2 was confirmed to have
spread to the peripheral organs by isolation of the virus after intra-
cerebral challenge, and that intra-cerebral challenge was a suitable
route for testing the ability of PAbs to provide either DENV-2
protection or AED in both the CNS and peripheral organs, 4) that
this was the first report in which severe, life-threatening DENV
acute respiratory distress syndrome (ARDS) was generated in an
animal model, 5) that this was also the first study to observe
increased megakaryocyte (platelet precursor) cell numbers result-
ing from DENV-2 AER/AED in an animal model, 6) that the
severe pathological findings in lung (ARDS), brain (encephalitis),
liver (necrosis and apoptosis (pyknosis), with macro- and micro-
steatosis) and spleen samples with DENV-2 antigen-positive tissue
macrophages from the DENV-2 AER/AED animals accorded
with those found in fatal human ‘severe dengue’ cases, and 7) that
candidate DENV NS1 glycoprotein-based vaccines may thus be
hazardous, particularly when used against DENV strains that
possess less antigenic NS1 glycoproteins.
These PAbs did not increase the replication of the prototype
DENV-2 NG-C strain, probably due to the stronger antigenicity of
its NS1 glycoprotein, which was supported by the ability of its NS1
glycoprotein to block the DENV-2 AER/AED caused by the NSx
strain. The NS1 glycoprotein of the DENV-2 NSx strain was,
therefore, chosen as a natural low passage DENV-2 isolate to
demonstrate the proof of principle that PAbs raised against the NS1
glycoprotein candidate vaccine could generate DENV-2 AER
under physiological conditions (i.e. undiluted PAbs in the presence
of complement and auto-antigens). Interestingly, a MAb generated
against the DENV prM glycoprotein that also cross-reacted with
proteins on mammalian cells generated DENV AER in the absence
of FcRs in vitro [65]. Thus, while the DENV-2 AER generated here
waslikelytobeFccR-dependent,thedualspecificitiesofthesePAbs,
against both the DENV-2 E glycoprotein and host cell-surface auto-
antigens [23–25] may also occur through a FccR-independent
mechanism. We opted to assess this possibility using panels of MAbs
(e.g. MAb 1G5.4-A1-C3), rather than these mouse PAbs which
contain antibodies of different IgG subclasses, since the double-
cleavage reactions required to obtain F(ab’)2 fragments of IgG1 and
other IgG subclasses [66,67] was likely to result in the disruption of
antigenic binding. This study demonstrates the first evidence that
PAbs raised against the DENV NS1 glycoprotein could generate a
dramatic AER of a DENV-2 strain in out-bred mice in vivo, with
lethalmulti-organ diseasesimilar to that observed inthe most severe
and lethal DSS cases. These results therefore raise further concerns,
in addition to the ability to generate auto-immune disease [24,25],
over the safety of any DENV NS1-based candidate vaccines.
The challenge route used for the DENV-2 NSx AER/AED
experiments was by intra-cerebral inoculation, as has been used as
for testing DENV active and passive protection experiments [46].
This model has therefore been extensively used to evaluate the
protective capacity of neutralizing PAbs and MAbs generated
against the DENV E and prM glycoproteins, as well as non-
neutralising PAbs and MAbs generated against the DENV NS1
and C proteins [47–52]. We have also generated this DENV-2
AER/AED in CD1 Swiss (out-bred) and BALB/c (inbred) mouse
Figure 5. Comparative DENV-2 AER/AED and non-AER/AED mouse lung histologies and DENV-2 AER/AED mouse liver and spleen
histologies. Representative DENV-2 AER/AED mouse lung, liver and spleen sections (A, C, D, E and F) from group A/B mice (Figure 2A/B) and DENV-2
non-AER/AED mouse lung sections (B) from group D mice (Figure 2D), immunized by the combined i-p/s-c. route with either the NS1 glycoprotein if
the DENV-2 NSx strain or ovalbumin, respectively, and challenged with the DENV-2 NSx strain by the i-c. route, collected on day 14 after challenge.
Cryostat-cut sections were either stained with H & E (A, B, C, D and F) or tested in immuno-fluorescence antibody (IFA) assays using human PAbs
reactive against the DENV E glycoprotein and FITC-labelled second PAbs (E). The DENV-2 AER/AED mouse lung showed extensive edema,
mononuclear cell infiltration with dramatic alveolar wall-thickening, protein-rich fluid-filled alveolar spaces (arrowed) and hyaline membrane
formation (200x: 50 mm bar) (A). In contrast, the DENV-2 non-AER/AED mouse lung showed slight oedema, with some alveolar walls still one cell thick
(arrowed) and no hyaline membrane formation (200x: 50 mm bar) (B). The DENV-2 AER/AED mouse liver showed some mononuclear cell infiltration,
macro-steatosis (asterixed) and micro-steatosis, with many cells displaying apoptosis (pyknotic nuclei) (some arrowed) (200x: 50 mm bar) (C). The
DENV-2 AER/AED mouse spleen contained numerous megakaryocytes, with characteristic multi-lobed nuclei, in the red pulp (arrowed) (D) but not
the white pulp (asterixed) (200x: 50 mm bar), with some arrowed in a higher magnification photomicrograph (400x: 25 mm bar) (F), and DENV-2 E
glycoprotein was found in the cells throughout the red pulp, but not the white pulp (asterixed) (200x: 50 mm bar) (E).
doi:10.1371/journal.pone.0021024.g005
Dengue Virus AER/AED
PLoS ONE | www.plosone.org 10 June 2011 | Volume 6 | Issue 6 | e21024strains, thereby suggesting that any mouse strain may be used for
this model (data not shown). In a previous study, we showed that
mice challenged with sub-lethal doses of DENV-2 by the intra-
cerebral route, generated peak titers 8 days later, but which
became undetectable on day 10 [9]. In contrast, lethal DENV-2
AER reached maximum titers on 9 days after challenge, and
remained the same until their deaths on day 12–14 after challenge
[9]. As such, the control mice generated much lower DENV-2
titers and showed no disease symptoms, probably due to DENV-2
clearance by the rising titers of protective PAbs. This was
consistent with our inability to detect any DENV-2 virus, antigens
or pathology in the brains of the non-AER/AED mice on day 14
after challenge in this study. Microglial cells are the principal
resident macrophages in the CNS, and which express all four
classes of mouse FccRs [68]. Their FccRI-expression was greatly
increased by IFN-c [69] and they were also activated by antigen-
IgG complexes binding to their Fc-cRIs (IgG2a only) and Fc-
cRIIIs [68], which resulted in MIP-1a-release and neuronal
apoptosis, and which has been implicated in a wide range of
neurological diseases [70]. Of particular concern is that DENV
encephalitis has increasingly been reported in both Asia and South
America [71], was the principal cause of encephalitis in one
DENV-endemic area [42], 7% in studies conducted in Jamaica
and Indonesia [43,44], and 4.6% in a study conducted in Viet
Nam, where Japanese encephalitis virus was prevalent [45].
DENV encephalitis has been associated with a poor patient
prognosis [41], and has been added as a symptom of ‘severe
dengue’ by the TDR/WHO steering committee [3]. Our DENV-
2 AER/AED model is, therefore, likely to be valuable in testing
potential therapies for these patients.
Despite using the unnatural intra-cerebral challenge route, the
DENV-2 was disseminated to the peripheral organs of the DENV-
2 AER/AED mice at the time of DENV-2 challenge when the
blood-brain barrier was breached, and bleeding was observed at
these injection sites. This was confirmed by isolation of DENV-2
by cell culture from the lungs, spleens and livers of the DENV-2
AER/AED mice on day 8–9 after challenge. These results,
therefore, support those previously found in liver samples of mice
after DENV challenge doses by the intra-cerebral route [53,54].
This challenge route, therefore, yielded very clear hind-leg
paralysis and life-threatening ARDS end-points for the DENV
AER/AED and blocking studies, which will be very useful for
passive protection studies using both PAbs and MAbs (see below).
We previously showed that some MAbs of the non-complement-
fixing IgG1 subclass (e.g. MAb 1G5.3) that were generated against
the DENV-2 NS1 glycoprotein identified common epitopes on the
DENV E glycoproteins, weakly neutralised them [23], and also
generated DENV-2 AED [9]. Affinity purified IgG obtained from
out-bred mice immunized with the DENV-2 NS1 glycoprotein
have also been used to generate DENV-2 AER/AED in naı ¨ve
mice after challenge with the DENV-2 NSx strain (Falconar,
manuscript in prep). MAbs of the IgG1, IgG2b and IgG2a
subclasses, some of which fixed serum complement (e.g. MAb
1G5.4-A1-C3: IgG2b subclass), and also defined common epitopes
on the DENV E and NS1 glycoproteins [23], have been tested for
their abilities to generate DENV AER/AED resulting in similar
multi-organ pathologies in mice (Falconar, manuscript in prep).
While there have been differences reported in the ability of
DENVs to infect cells of the non-monocyte/macrophage lineages
(e.g. lymphocytes, hepatocytes, endothelial cells and megakaryo-
cytes) [5,26–34,72,73], Fc receptor bearing monocytes and tissue
macrophages are universally considered to be the principal target
cells for DENV replication. This was confirmed in the DENV-2
AER/AED mice by finding that, with the exception of
hepatocytes, DENV-2 antigens were only found in tissue
macrophages possessing their characteristic morphologies, in each
of the organs studied (lungs, livers, spleens and brains). In our
study, we also observed that much higher percentages of the
macrophages present in the splenic red pulp and liver, rather than
the lungs, contained DENV-2 E glycoproteins, consistent with the
spleen, as well as the liver, being a principal site for DENV
replication [27], together with high megakaryocte numbers in the
spleen. This was, therefore, the first observation of increased
megakaryocyte numbers in animals infected with DENV, as has
been a frequent observation in histological studies on DHF/DSS
patient autopsies [5,26]. Young megakaryocytes were, however,
reported to be present in both the bone marrow and peripheral
organs of DHF/DSS patients [5,74], but in other reports these
increased numbers of megakaryocytes displayed vacuolation or
disintegration, which subsequently resulted in bone marrow
suppression [72,73]. Since the megakaryocytes located in the
splenic red pulp of the DENV-2 AER/AED mice were
morphologically mature, further studies are required to account
for these different observations.
Interestingly, pulmonary congestion with liver steatosis was
observed in BALB/c after the administration of high doses of a
low-passage DENV-2 strain by the peripheral route [75]. These
symptoms were, therefore, similar to those observed in our study,
but those mice only transiently displayed the severe lung
congestion before it was resolved, and no mortalities occurred.
In contrast, the ARDS was sufficiently severe and prolonged
(studied on day 14 after DENV challenge) in our DENV-2 AER/
AED mice, that it per se could cause death, and probably also
contributed to the severe liver necrosis with macro- and micro-
steatosis observed in these animals, since multi-organ or systemic
pathology due to hypoxia and metabolic acidosis are common
complications of ARDS [76,77]. Importantly, in several reports
ARDS was the main cause of mortality in DSS patients either
alone or through its cause of, or contribution to, multi-organ
failure and DIC, and this often caused death even when these
patients received early fluid replacement [36–39], and after their
plasma leakage was resolved [26]. The previous results [75],
together with finding of severe pathology in the peripheral organs
of the DENV-2 AER/AED mice, from which DENV-2 was
isolated, strongly suggest that our DENV-2 AER/AED model
may also be used when the DENV-2 NSx strain is delivered by the
intra-peritoneal challenge route. This is therefore the first report
demonstrating severe life-threatening DENV-2 induced ARDS in
an animal model. Further studies are also needed however to
identify the role of auto-antibody reactions [24,25], complement,
and cytokines/chemokines secreted from different macrophage
populations and T-cells in the different organ pathologies observed
in these mice.
AG129 mice, deficient in IFN-a, b and c receptors, generated
antibodies of IgG1, but not the IgG2a, subclasses [78], were also
not protected by MAbs of the IgG2a subclass (e.g. MAb 4G2: CF
titer: 1/16 [56]) when administered at 50 mg concentrations that
would solidly protect normal mice [79]. AG129 mice also did not
show pathological symptoms in their lungs when infected with
different DENV-2 strains [80,81], or when low concentrations of
PAbs, generated against live DENV-1 infections in AG129 mice,
were passively administered (100 ml of serum/mouse) to naı ¨ve
AG129 mice before challenge with DENV-2 [82]. These results
were in stark contrast to those observed in our normal mice, and in
fatal DSS cases [5,26], probably due to the failure of AG129 mice
to activate their macrophages and other ADCCs with IFN-c [83].
This would be consistent with the higher levels of IFN-c and
macrophage-activation reported in DHF/DSS patients [84,85].
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titers, resulted in rapidly reduced DENV-2 replication in A/J
mouse spleens [86]. Similarly, peak DENV-2 titers occurred in the
spleens of AG129 mice, before being reduced soon after DENV
challenge [81,87,88]. Thus, our ability to isolate the DENV-2
from lung, spleen and liver samples collected on day 8-9 after
challenge suggested that clearance from these organs was delayed
due to its AER.
Since the DENV E and NS1 glycoproteins appeared to co-
evolve antigenically [89], variations in their antigenicities and
therefore their potentials to generate AER/AED are likely to
occur through mutations or genetic recombination events.
Recombination has been identified in the genes encoding the E
and NS1 glycoproteins of a number of DENV strains of the same,
as well as different genotypes [90–92], and in one study occurred
between strains of the DENV-2 American (weakly pathogenic),
Asian/American (highly pathogenic) and Cosmopolitan (patho-
genic) genotypes [92]. The NS1 glycoprotein of the DENV-2 NSx
strain therefore appeared to have a reduced antigenicity due to
either multiple amino acid substitutions, or possibly by a major
recombination event between heterologous DENV-2 genotypes or
a different DENV serotype. These possibilities are being
investigated using DENV-2 NSx cDNA sequence determination
and AER/AED studies using panels of MAbs generated against
the DENV NS1 glycoprotein, which defined single or multiple
epitopes on DENV NS1 and E glycoproteins of different DENV
strains [23–25].
Most importantly, blocking DENV AER/AED to prevent the
ARDS and multiple organ dysfunction syndrome (MODS), would
be particularly useful for DSS patients.
Supporting Information
Figure S1 Immunoblot reactions of immuno-affinity
purified NS1 glycoproteins. High (960 ng) concentrations of
purified DENV-2 (NSx strain) virions (lanes 1 and 5) and high
(200 ng) concentrations of the purified e/sNS1 glycoproteins of the
16681 (lanes 2 and 6), NG-C (lanes 3 and 7) and NSx (lanes 4 and
8) were heated at 100uC for 3 min and subjected to 8% (wt/vol)
non-reduced SDS-PAGE and immuno-blotting. These strips were
then reacted with 1 mg/ml concentrations of MAbs specific for
either the DENV NS1 (MAb 2A5.1) glycoprotein (lanes 1 to 4) or
the E (MAb 2C5.1) and prM (MAb 2A4.1) (lanes 5 to 8)
glycoproteins. The bound MAbs were then detected using
peroxidise-labelled anti-mouse IgG2a subclass-specific secondary
PAbs and CND substrate. The location of the standard kD
molecular weight markers and the DENV-2 E (gp60/55), e/sNS1
(gp48) and prM (gp20) glycoproteins are shown.
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